Statements (30)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:approvedBy |
1962
|
| gptkbp:ATCCode |
M03BX09
|
| gptkbp:brand |
gptkb:Skelaxin
|
| gptkbp:CASNumber |
1665-48-1
|
| gptkbp:chemicalFormula |
C12H15NO3
|
| gptkbp:contraindication |
gptkb:anemia
severe renal impairment severe hepatic impairment |
| gptkbp:drugClass |
skeletal muscle relaxant
|
| gptkbp:eliminationHalfLife |
2.4 hours
|
| gptkbp:FDAApproved |
yes
|
| https://www.w3.org/2000/01/rdf-schema#label |
metaxalone
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:manufacturer |
gptkb:King_Pharmaceuticals
|
| gptkbp:mechanismOfAction |
central nervous system depression
|
| gptkbp:metabolism |
liver
|
| gptkbp:molecularWeight |
221.25 g/mol
|
| gptkbp:pregnancyCategory |
C (US)
|
| gptkbp:prescribes |
adults and children over 12 years
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
nausea
dizziness headache drowsiness |
| gptkbp:synonym |
gptkb:Metaxalona
|
| gptkbp:usedFor |
muscle pain
musculoskeletal conditions |
| gptkbp:bfsParent |
gptkb:Skelaxin
|
| gptkbp:bfsLayer |
6
|